Holen Sie sich die Stockscreener-App
15.53
0.84%
0.13
Handel nachbörslich:
15.84
0.31
+2.00%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt TVTX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$15.40
Offen:
$15.57
24-Stunden-Volumen:
1.03M
Relative Volume:
0.65
Marktkapitalisierung:
$1.38B
Einnahmen:
$203.45M
Nettoeinkommen (Verlust:
$-351.45M
KGV:
-3.4132
EPS:
-4.55
Netto-Cashflow:
$-369.41M
1W Leistung:
-0.83%
1M Leistung:
+5.15%
6M Leistung:
-24.06%
1J Leistung:
+52.40%
1-Tages-Spanne:
$15.32
$15.76
1-Wochen-Bereich:
$15.28
$16.17
52-Wochen-Spanne:
$7.931
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Firmenname
Travere Therapeutics Inc
Sektor
Branche
Telefon
888-969-7879
Adresse
3611 VALLEY CENTRE DR, SAN DIEGO
Vergleichen Sie TVTX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
15.53 | 1.37B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-11 | Bestätigt | Citigroup | Buy |
| 2025-06-11 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-10-21 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-09-09 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-03-27 | Herabstufung | Guggenheim | Buy → Neutral |
| 2023-12-05 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-11-20 | Eingeleitet | Citigroup | Neutral |
| 2023-09-22 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-09-21 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-09-06 | Fortgesetzt | Evercore ISI | Outperform |
| 2023-07-21 | Eingeleitet | JP Morgan | Overweight |
| 2023-06-07 | Fortgesetzt | Piper Sandler | Neutral |
| 2023-05-22 | Eingeleitet | TD Cowen | Outperform |
| 2023-05-05 | Hochstufung | Bryan Garnier | Sell → Neutral |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2023-02-21 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-12-14 | Eingeleitet | Stifel | Hold |
| 2022-12-05 | Eingeleitet | Wells Fargo | Overweight |
| 2022-09-21 | Eingeleitet | Bryan Garnier | Sell |
| 2022-07-14 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-03-31 | Eingeleitet | Piper Sandler | Overweight |
| 2022-02-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-05-26 | Herabstufung | Wedbush | Outperform → Neutral |
Alle ansehen
Travere Therapeutics Inc Aktie (TVTX) Neueste Nachrichten
Why is Travere Therapeutics Inc. stock attracting strong analyst attentionStock Market Guidance With High Returns - jammulinksnews.com
What are Travere Therapeutics Inc. company’s key revenue driversGet timely alerts on market opportunities - jammulinksnews.com
How does Travere Therapeutics Inc. compare to its industry peersGet alerts on the hottest market movers - jammulinksnews.com
How does Travere Therapeutics Inc. generate profit in a changing economyOutstanding capital returns - jammulinksnews.com
How many analysts rate Travere Therapeutics Inc. as a “Buy”Unlock powerful stock screening for profits - jammulinksnews.com
When is Travere Therapeutics Inc. stock expected to show significant growthAccelerated capital growth - jammulinksnews.com
What are analysts’ price targets for Travere Therapeutics Inc. in the next 12 monthsFree Trading Strategy Suggestions - jammulinksnews.com
Why Travere Therapeutics Inc. stock attracts strong analyst attentionProfitable Yet Secure Picks - metal.it
Is Travere Therapeutics Inc. a good long term investmentRapid portfolio appreciation - PrintWeekIndia
What drives Travere Therapeutics Inc. stock priceExceptional profit potential - PrintWeekIndia
Travere Therapeutics Inc. Stock Analysis and ForecastSuperior portfolio returns - Autocar Professional
What analysts say about Travere Therapeutics Inc. stockTremendous wealth creation - PrintWeekIndia
What analysts say about Travere Therapeutics Inc. stock outlookMassive wealth growth - jammulinksnews.com
Travere Therapeutics, Inc. (NASDAQ:TVTX): Is Breakeven Near? - 富途牛牛
Travere Therapeutics anticipates FILSPARI approval for FSGS by September 2025 - MSN
Nisa Investment Advisors LLC Trims Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Where are the Opportunities in (TVTX) - news.stocktradersdaily.com
Research Analysts Set Expectations for TVTX FY2025 Earnings - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Teacher Retirement System of Texas - Defense World
Finanzdaten der Travere Therapeutics Inc-Aktie (TVTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
10.28%
2.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):